Sec. 102. Drug supply quality and safety. 
Sec. 103. Inspection of producers of drugs. 
Sec. 104. Prohibition against delaying, limiting, or refusing inspection. 
Sec. 105. Clarification of inspection authority related to BIMO and IRB inspec-
tions. 
Sec. 106. Notification, nondistribution, and recall of adulterated or misbranded 
drug products. 
Sec. 107. Notification. 
TITLE II—RESPONSE 
Sec. 201. Administrative detention. 
Sec. 202. Destruction of adulterated, misbranded, or counterfeit drugs offered 
for import. 
Sec. 203. Criminal penalties. 
Sec. 204. Civil penalties. 
Sec. 205. Seizure. 
Sec. 206. Asset forfeiture. 
TITLE III—IMPORTATION AND EXPORTATION 
Sec. 301. Documentation for admissibility of imports. 
Sec. 302. Registration for commercial importers; fee. 
Sec. 303. Registration for customs brokers. 
Sec. 304. Exportation certificate program. 
Sec. 305. Extraterritorial jurisdiction. 
Sec. 306. Dedicated foreign inspectorate. 
TITLE IV—MISCELLANEOUS 
Sec. 401. Unique identification number for establishments, importers, and cus-
toms brokers. 
Sec. 402. Country of origin labeling. 
Sec. 403. False or misleading reporting to FDA. 
Sec. 404. Subpoena authority. 
Sec. 405. Whistleblower protections. 
Sec. 406. Rule of construction. 
TITLE I—PREVENTION 
SEC. 101. REGISTRATION OF PRODUCERS OF DRUGS; AP-
PLICABLE FEE. 
(a) FOREIGN REGISTRANTS.— 
(1) MISBRANDING.—Section 502(o) of the Fed-
eral, Food, Drug, and Cosmetic Act (21 U.S.C. 
352(o)) is amended by inserting ‘‘if it is a drug and 
was manufactured, prepared, propagated, com-
pounded, or processed in an establishment not duly 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
registered under section 510(i),’’ after ‘‘not duly 
registered under section 510,’’. 
(2) APPLICATION.—The amendment made by 
paragraph (1) applies only with respect to registra-
tion (including failure to register) under section 510 
of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 360) occurring on or after the date of the en-
actment of this Act. 
(b) EXCIPIENT MANUFACTURERS.— 
(1) IN
GENERAL.—Not later than 6 months 
after the date of the enactment of this Act, the Sec-
retary of Health and Human Services shall revise 
section 207.10 of title 21, Code of Federal Regula-
tions, and such other regulations as may be nec-
essary to require owners and operators of establish-
ments that engage in the manufacture, preparation, 
propagation, compounding, or processing of an ex-
cipient of a drug to register such establishments 
under section 510 of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 360). 
(2) APPLICATION.—The revisions to regulations 
under paragraph (1) shall apply with respect to the 
manufacture, 
preparation, 
propagation, 
compounding, or processing of an excipient of a drug 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
on or after the date that is 18 months after the date 
of the enactment of this Act. 
(c) DRUG LISTING ELEMENTS AND FREQUENCY.— 
(1) IN GENERAL.—Sections 510(j) of the Fed-
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
360(j)) is amended— 
(A) in paragraph (1), by amending sub-
paragraph (C) to read as follows: 
‘‘(C) in the case of any drug contained in an 
applicable list which is described in subparagraph 
(A) or (B), a qualitative and quantitative listing of 
each of its active and other ingredients, and any 
other information that the Secretary finds is nec-
essary to carry out the purposes of this Act; and’’; 
and 
(B) in paragraph (2), in the matter pre-
ceding subparagraph (A), by inserting ‘‘, unless 
otherwise specified by the Secretary’’ after 
‘‘once during the month of December of each 
year’’. 
(2) APPLICATION.—The amendments made by 
paragraph (1) apply with respect to the filing of a 
list under section 510(j) of the Federal Food, Drug, 
and Cosmetic Act (21 U.S.C. 360(j)) that occurs on 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
or after the date that is 6 months after the date of 
the enactment of this Act. 
(d) SUSPENSION AND CANCELLATION OF REGISTRA-
TION.—Section 510 of the Federal Food, Drug, and Cos-
metic Act (21 U.S.C. 360j) is amended by adding at the 
end the following: 
‘‘(q) SUSPENSION
AND CANCELLATION
OF REG-
ISTRATION.—With respect to any registration under this 
section attributable to the manufacture, preparation, 
propagation, compounding, or processing of a drug: 
‘‘(1) SUSPENSION OF REGISTRATION.— 
‘‘(A) IN
GENERAL.—Registration under 
this section is subject to suspension upon a 
finding by the Secretary, after notice and an 
opportunity for an informal hearing, of— 
‘‘(i) a violation of this Act; or 
‘‘(ii) the knowing or repeated making 
of an inaccurate or incomplete statement 
or submission of information relating to 
the manufacture, preparation, propagation, 
compounding, processing, or importing of a 
drug. 
‘‘(B) REQUEST.—Any person or establish-
ment whose registration is suspended under 
subparagraph (A) may request that the Sec-
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
retary vacate the suspension when such person 
or establishment has corrected the violation 
that is the basis for such suspension. 
‘‘(C) VACATING OF SUSPENSION.—If the 
Secretary determines that adequate reasons do 
not exist to continue the suspension of a reg-
istration under subparagraph (A), the Secretary 
shall vacate such suspension. 
‘‘(2) CANCELLATION OF REGISTRATION.— 
‘‘(A) IN GENERAL.—Not earlier than 10 
days after providing the notice under subpara-
graph (B), the Secretary may cancel a registra-
tion if the Secretary determines that— 
‘‘(i) such registration was not updated 
in accordance with this section or contains 
false, incomplete, or inaccurate informa-
tion; or 
‘‘(ii) the fee required under section 
736C for such registration has not been 
paid within 30 days after the date due. 
‘‘(B) NOTICE OF CANCELLATION.—Before 
cancelling the registration of a person or estab-
lishment under this section, the Secretary shall 
give notice to the person or establishment of the 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
Secretary’s intent to cancel the registration and 
the basis for such cancellation. 
‘‘(C) TIMELY UPDATE OR CORRECTION.— 
If a registration is adequately updated or cor-
rected no later than 7 days after notice is pro-
vided under subparagraph (B) with respect to 
the registration, the Secretary shall not cancel 
such registration.’’. 
(e) REGISTRATION FEE.— 
(1) ESTABLISHMENT.—Part 2 of subchapter C 
of chapter VII of the Federal Food, Drug, and Cos-
metic Act (21 U.S.C. 379g et seq.) is amended by 
adding at the end the following: 
‘‘SEC. 736C. REGISTRATION FEE. 
‘‘(a) IN GENERAL.—In the case of any registration 
under section 510 that is attributable to the manufacture, 
preparation, propagation, compounding, processing, or im-
porting of a drug, the Secretary shall assess and collect 
an annual fee for such registration to defray the increase 
in the costs of drug safety activities. 
‘‘(b) PAYABLE DATE.—A fee under this section shall 
be payable— 
‘‘(1) for a facility that was not registered under 
section 510 for the preceding fiscal year, on the date 
of registration; and 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
shall establish registration fees under subsection 
(a)— 
‘‘(A) based on the total revenue amount 
applicable under paragraph (1); and 
‘‘(B) taking into consideration the dif-
ference in costs of inspections between foreign 
and domestic establishments. 
‘‘(3) TRANSMISSION TO CONGRESS.—Not later 
than 60 days before the start of fiscal year 2012 
and each subsequent fiscal year, the Secretary shall 
transmit to the Congress— 
‘‘(A) the total revenue amount for the up-
coming fiscal year, as applicable under para-
graph (1); and 
‘‘(B) the registration fees for such year, as 
established under paragraph (2). 
‘‘(d) INFLATION
ADJUSTMENT.—For fiscal year 
2013 and subsequent fiscal years, the fee amount under 
subsection (c) shall be adjusted by the Secretary by notice, 
published in the Federal Register, for the respective fiscal 
year to reflect the greater of— 
‘‘(1) the total percentage change that occurred 
in the Consumer Price Index for all urban con-
sumers (all items; United States city average) for 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
the 12-month period ending June 30 preceding the 
fiscal year for which fees are being established; 
‘‘(2) the total percentage change for the pre-
vious fiscal year in basic pay under the General 
Schedule in accordance with section 5332 of title 5, 
United States Code, as adjusted by any locality- 
based comparability payment pursuant to section 
5304 of such title for Federal employees stationed in 
the District of Columbia; or 
‘‘(3) the average annual change in the cost, per 
full-time equivalent position of the Food and Drug 
Administration, of all personnel compensation and 
benefits paid with respect to such positions for the 
first 5 years of the preceding 6 fiscal years. 
The adjustment made each fiscal year under this sub-
section will be added on a compounded basis to the sum 
of all adjustments made each fiscal year after fiscal year 
2011 under this subsection. 
‘‘(e) FEE WAIVER OR REDUCTION.—The Secretary 
may grant to a person a waiver from, or a reduction of, 
one or more fees under this section if the Secretary finds 
that— 
‘‘(1) such waiver or reduction is necessary to 
protect the public health; or 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
‘‘(2) the assessment of the fee would impose 
significant financial hardship because of limited re-
sources available to such person or other cir-
cumstances. 
‘‘(f) LIMITATIONS.— 
‘‘(1) IN GENERAL.—Fees under subsection (a) 
shall be refunded for a fiscal year beginning after 
fiscal year 2012 unless appropriations for salaries 
and expenses of the Food and Drug Administration 
for such fiscal year (excluding the amount of fees 
appropriated for such fiscal year) are equal to or 
greater than the amount of appropriations for the 
salaries and expenses of the Food and Drug Admin-
istration for the fiscal year 2012 (excluding the 
amount of fees appropriated for such fiscal year) ad-
justed in the same manner that fee amounts are ad-
justed under subsection (d). 
‘‘(2) AUTHORITY.—If the Secretary does not 
assess fees under subsection (a) during any portion 
of a fiscal year because of paragraph (1) and if at 
a later date in such fiscal year the Secretary may as-
sess such fees, the Secretary may assess and collect 
such fees, without any modification in the rate, for 
registration under section 510 at any time in such 
fiscal year. 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
‘‘(g) CREDITING AND AVAILABILITY OF FEES.— 
‘‘(1) IN GENERAL.—Fees authorized under sub-
section (a) shall be collected and available for obliga-
tion only to the extent and in the amount provided 
in advance in appropriations Acts. Such fees are au-
thorized to remain available until expended. Such 
sums as may be necessary may be transferred from 
the Food and Drug Administration salaries and ex-
penses appropriation account without fiscal year lim-
itation to such appropriation account for salaries 
and expenses with such fiscal year limitation. 
‘‘(2) 
COLLECTIONS
AND
APPROPRIATIONS 
ACTS.—The fees authorized by this section— 
‘‘(A) shall be retained in each fiscal year in 
an amount not to exceed the amount specified 
in appropriations Acts, or otherwise made avail-
able for obligation, for such fiscal year; and 
‘‘(B) shall only be collected and available 
to defray the costs of drug safety activities. 
‘‘(3) AUTHORIZATION
OF
APPROPRIATIONS.— 
For each of the fiscal years 2012 through 2016, 
there are authorized to be appropriated for fees 
under this section such sums as may be necessary. 
‘‘(h) COLLECTION OF UNPAID FEES.—In any case 
in which the Secretary does not receive payment of a fee 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
assessed under subsection (a) within 30 days after it is 
due, such fee shall be treated as a claim of the United 
States Government subject to subchapter II of chapter 37 
of title 31, United States Code. 
‘‘(i) CONSTRUCTION.—This section may not be con-
strued to require that the number of full-time equivalent 
positions in the Department of Health and Human Serv-
ices, for officers, employers, and advisory committees not 
engaged in drug safety activities, be reduced to offset the 
number of officers, employees, and advisory committees so 
engaged. 
‘‘(j) ANNUAL FISCAL REPORTS.—Beginning with fis-
cal year 2013, not later than 120 days after the end of 
each fiscal year for which fees are collected under this sec-
tion, the Secretary shall prepare and submit to the Com-
mittee on Energy and Commerce of the House of Rep-
resentatives and the Committee on Health, Education, 
Labor, and Pensions of the Senate a report on the imple-
mentation of the authority for such fees during such fiscal 
year and the use, by the Food and Drug Administration, 
of the fees collected for such fiscal year. 
‘‘(k) RELATION TO OTHER FEES.—Fees assessed 
and collected under this section are in addition to other 
fees assessed and collected under this Act with respect to 
the same person or establishment. 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
‘‘(l) DEFINITIONS.—In this section: 
‘‘(1) The term ‘costs of drug safety activities’ 
means the expenses incurred in connection with drug 
safety activities for— 
‘‘(A) officers and employees of the Food 
and Drug Administration, contractors of the 
Food and Drug Administration, advisory com-
mittees, and costs related to such officers, em-
ployees, and committees and to contracts with 
such contractors; 
‘‘(B) laboratory space; 
‘‘(C) management of information, and the 
acquisition, maintenance, and repair of infor-
mation technology resources; 
‘‘(D) leasing, maintenance, renovation, and 
repair of facilities and acquisition, maintenance, 
and repair of fixtures, furniture, scientific 
equipment, and other necessary materials and 
supplies; and 
‘‘(E) collecting fees under this section and 
accounting for resources allocated for drug 
safety activities. 
‘‘(2) The term ‘drug safety activities’ means ac-
tivities related to compliance by persons and estab-
lishments registered under section 510 with the re-
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
quirements of this Act relating to drugs (including 
research related to and the development of stand-
ards (such as performance standards and preventive 
controls), risk assessments, hazard analyses, inspec-
tion planning and inspections, third-party inspec-
tions, compliance review and enforcement, import re-
view, information technology support, test develop-
ment, product sampling, risk communication, and 
administrative detention).’’. 
(2) TRANSITIONAL PROVISIONS.— 
(A) FIRST
IMPOSITION
OF
FEES.—The 
Secretary of Health and Human Services shall 
first impose the fee established under section 
736C of the Federal Food, Drug, and Cosmetic 
Act, as added by paragraph (1), for fiscal years 
beginning with fiscal year 2012. 
(B) SUNSET DATE.—Section 736C of the 
Federal Food, Drug, and Cosmetic Act, as 
added by paragraph (1), does not authorize the 
assessment or collection of a fee for registration 
under section 510 of such Act (21 U.S.C. 360) 
occurring after fiscal year 2016. 
(f) MODIFICATION OF REGISTRATION FORM.—Not 
later than 180 days after the date of the enactment of 
this Act, the Secretary of Health and Human Services 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
shall modify the registration forms under section 510 of 
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
350d) to comply with the amendments made by this sec-
tion. 
SEC. 102. DRUG SUPPLY QUALITY AND SAFETY. 
(a) DEFINITIONS.—Section 201(g) of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 321(g)) is 
amended by adding at the end the following: 
‘‘(3) In the case of a drug, the term ‘component’ in-
cludes— 
‘‘(A) any active ingredient or bulk drug sub-
stance; 
‘‘(B) any inactive ingredient; 
‘‘(C) any intermediate of an active ingredient, 
inactive ingredient, or bulk drug substance, whether 
or not it appears in the finished product and wheth-
er or not derived from any chemical, human, animal, 
plant, or other material; and 
‘‘(D) any original source material for compo-
nents specified in clauses (A), (B), and (C) whether 
or not the original source material— 
‘‘(i) appears in the finished product; and 
‘‘(ii) is derived from any chemical, human, 
animal, plant, or other material.’’. 
(b) EFFECTIVE QUALITY SYSTEMS.— 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
(1) PROHIBITED ACTS.— 
(A) RECORDKEEPING.—Section 301(e) of 
the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 331(e)) is amended— 
(i) 
by 
inserting 
‘‘503C,’’ 
after 
‘‘417(j),’’; and 
(ii) 
by 
inserting 
‘‘503C,’’ 
after 
‘‘417,’’. 
(B) ADULTERATION.—Section 501 of the 
Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 351) is amended by adding at the end 
the following: 
‘‘(j) If it is a drug that was manufactured (as defined 
in section 503C) by a manufacturer that is or was at the 
time of such manufacture in violation of section 503C be-
cause of the failure to have in effect or implement an effec-
tive quality system in accordance with such section.’’. 
(2) SYSTEM
REQUIREMENTS.—The Federal 
Food, Drug, and Cosmetic Act is amended by insert-
ing after section 503B (21 U.S.C. 353b) the fol-
lowing: 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
‘‘SEC. 503C. EFFECTIVE QUALITY SYSTEM FOR DRUG MANU-
FACTURERS. 
‘‘(a) IN GENERAL.—Each manufacturer of a drug re-
quired to be registered under section 510 shall have in 
effect and implement an effective quality system. 
‘‘(b) SYSTEM REQUIREMENTS.—An effective quality 
system applicable to a manufacturer of a drug under sub-
section (a) shall require each of the following: 
‘‘(1) 
MANAGEMENT
RESPONSIBILITY.—The 
manufacturer shall ensure that— 
‘‘(A) adequate resources are provided to 
ensure compliance with current good manufac-
turing practice; 
‘‘(B) procedures are established and main-
tained to ensure timely communication of prod-
uct quality issues to appropriate levels of man-
agement, including executive management; 
‘‘(C) periodic reviews of process perform-
ance, product quality, and other elements of the 
quality system are conducted; 
‘‘(D) the periodic reviews under subpara-
graph (C) are evaluated by executive manage-
ment to determine any appropriate action; and 
‘‘(E) the integrity of data, records, and 
regulatory submissions, including with respect 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
to accuracy, veracity, and validity, is main-
tained. 
‘‘(2) QUALITY RESPONSIBILITY.— 
‘‘(A) INTERNAL, INDEPENDENT
UNIT.— 
The manufacturer shall establish and maintain 
an internal, independent unit with the authority 
to ensure that all operations related to manu-
facturing drugs, including those performed by 
another person, are appropriately designed, ap-
proved, conducted, monitored, and corrected in 
compliance with current good manufacturing 
practice. 
‘‘(B) PROCEDURES.—The manufacturer 
shall establish and maintain procedures to en-
sure that— 
‘‘(i) any discrepancy related to manu-
facturing 
a 
drug 
(including 
the 
discrepancy’s causes) is promptly identi-
fied, investigated, and corrected, the recur-
rence of the discrepancy is prevented, and 
any corrective or preventive action is 
verified or validated to ensure that such 
action is effective and does not adversely 
affect the drug; and 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
‘‘(ii) ongoing reviews of all data re-
lated to manufacturing a drug are con-
ducted to identify trends that might affect 
product quality and timely actions are per-
formed to prevent any adverse effect on 
product safety, identity, quality, strength, 
or purity. 
‘‘(3) RISK
MANAGEMENT.—The manufacturer 
shall establish and maintain risk management proce-
dures that ensure effective risk assessment, control, 
and communication. The risk assessment procedures 
shall ensure that all factors throughout the supply 
chain that may reasonably be expected to indicate a 
risk to the safety, identity, quality, strength, purity, 
or security of any drug manufactured by that manu-
facturer are identified, starting with factors relating 
to origin of all components including the original 
source materials; information relating to all such 
factors is continuously gathered, monitored, and 
evaluated; and new factors are promptly identified. 
‘‘(4) SUPPLY CHAIN MANAGEMENT.— 
‘‘(A) IN
GENERAL.—The manufacturer 
shall establish and maintain procedures that en-
sure the safety, identity, quality, strength, pu-
rity, and security of all drugs and other mate-
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
rials used by that manufacturer. The supply 
chain procedures shall address the entire supply 
chain from original source materials used in the 
manufacture of the drug to the manufacturer. 
The supply chain procedures shall ensure that 
there is adequate followup, which shall include 
no longer receiving any source materials or 
drugs from, or using operations conducted by, 
any person who fails to implement timely cor-
rections for supply chain management practices 
or other applicable requirements under this Act 
or sections 351 or 361 of the Public Health 
Service Act. 
‘‘(B) PROCEDURES.—Supply chain man-
agement procedures under subparagraph (A) 
shall include— 
‘‘(i) acceptance and rejection criteria 
for each component that ensures that such 
component is appropriate for its intended 
use and that include, unless not feasible 
using current technology, a sufficient im-
purity profile for each component, includ-
ing each component that is naturally de-
rived, except that the requirements of this 
clause shall not apply to any component of 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
a licensed biological product unless re-
quired under the license issued for such 
product under section 351 of the Public 
Health Service Act or under paragraph 
(5); 
‘‘(ii) onsite audits, performed by 
qualified individuals, of each person that 
supplies a drug or conducts operations re-
lated to manufacturing, before such person 
begins initial supply or operation and at an 
appropriate frequency to assess the contin-
ued compliance of such person with the 
manufacturer’s supply chain practices and 
with the applicable requirements under this 
Act and sections 351 and 361 of the Pub-
lic Health Service Act; 
‘‘(iii) requirements for a quality 
agreement with any person who supplies a 
drug or conducts operations related to 
manufacturing a drug which addresses all 
applicable current good manufacturing 
practice requirements; 
‘‘(iv) the sharing of manufacturing in-
formation by any person who supplies a 
drug or conducts operations related to 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00022
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
manufacturing, including timely notifica-
tion concerning any change to, discrepancy 
in, or defect in, materials or operations re-
lated to manufacturing, along with ade-
quate information about such change, dis-
crepancy, or defect; 
‘‘(v) when supplying any drug to an-
other manufacturer, provision of a certifi-
cate of analysis for each batch and lot that 
includes complete source, manufacturing, 
and test information and results; and 
‘‘(vi) methods, which shall include ac-
ceptance and rejection criteria, adequate— 
‘‘(I) to detect, or exclude the pos-
sibility of, the presence of any sub-
stance that may reasonably be ex-
pected to indicate a risk to safety, 
identity, quality, strength, purity, or 
security; and 
‘‘(II) to detect, or exclude the 
possibility of, other risks to safety, 
identity, quality, strength, purity, or 
security. 
‘‘(5) METHODS.— 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00023
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
‘‘(A) IN
GENERAL.—Each manufacturer 
shall establish and maintain procedures that en-
sure— 
‘‘(i) periodic evaluation and, where 
necessary, prompt revision of methods, in-
cluding acceptance and rejection criteria, 
to ensure the safety, identity, quality, 
strength, purity, and security of each drug 
manufactured by such manufacturer, or 
component used in the manufacture of 
such drug; 
‘‘(ii) when any new risk is identified— 
‘‘(I) adoption of appropriate re-
vised or new methods; and 
‘‘(II) evaluation of every batch 
and lot of drug using such revised 
methods; and 
‘‘(iii) if required, an application is 
submitted for timely approval by the Sec-
retary of the revised or new methods under 
section 505, 506A, 512, or 571 of this Act 
or section 351 of the Public Health Service 
Act. 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00024
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
‘‘(B) DETERMINATION
OF
RISK.—Each 
evaluation and revision under subparagraph 
(A)(i) shall be based on a determination of risk. 
‘‘(C) NOTIFICATION REGARDING REVISED 
METHOD.—Each manufacturer of a drug shall 
promptly notify the Secretary and the appro-
priate body charged with revision of an official 
compendium of any revised method for such 
drug and its rationale. Such notification shall 
be made in such form and manner as the Sec-
retary shall prescribe by regulation. 
‘‘(D) ORDERS
REGARDING
REVISED
OR 
NEW
METHODS.—If the Secretary determines 
that a revised or new method, including accept-
ance and rejection criteria, is appropriate for 
the safety, identity, quality, strength, purity, or 
security of any drug, the Secretary may by let-
ter order any manufacturer of such drug to 
promptly— 
‘‘(i) revise any method, or adopt any 
new method, and any related acceptance 
and rejection criteria for such drug; and 
‘‘(ii) implement such revised or new 
method and any related acceptance and re-
jection criteria. 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00025
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS
‘‘(6) RECORDS.— 
‘‘(A) IN
GENERAL.—Each manufacturer 
shall 
maintain 
adequate, 
contemporaneous 
records (which may be electronic) to document 
conformity with requirements under this sec-
tion. Such records shall be accurate, indelible, 
and legible. Each manufacturer shall establish 
and maintain a procedure to ensure the identi-
fication, storage, protection, retrieval, retention, 
and disposition of such records. 
‘‘(B) MAINTENANCE OF RECORDS; INSPEC-
TION.—Each 
manufacturer 
shall 
maintain 
records under subparagraph (A) for at least 2 
years from the date of the expiration date of 
the drug involved and make such records read-
ily available for inspection by the Secretary. 
Such records or copies thereof shall be subject 
to photocopying or other means of reproduction 
as part of such inspection. Each manufacturer 
shall provide to the Secretary these records or 
copies thereof in a timely manner, upon verbal 
or written request by an officer or employee 
duly designated by the Secretary. 
‘‘(7) ADDITIONAL
PROVISIONS.—If the Sec-
retary determines that provisions in addition to 
VerDate Mar 15 2010 
22:22 Apr 13, 2011
Jkt 099200
PO 00000
Frm 00026
Fmt 6652
Sfmt 6201
E:\BILLS\H1483.IH
H1483
emcdonald on DSK2BSOYB1PROD with BILLS